Krystal Biotech (NASDAQ: KRYS) Price Target Raised by Citigroup (NYSE: C) Amid Vyjuvek Success and KB113 Progress

• Citigroup (NYSE: C) raised its price target for Krystal Biotech (NASDAQ: KRYS) to $416.00 from $386.00, indicating a potential 24.8% upside from current trading levels.
• Krystal Biotech's approved product, Vyjuvek, generated $119.2 million in Q2 revenue, contributing to a strong financial position with $1.1 billion in cash and a 40% operating margin.
• Early clinical data for Krystal Biotech's KB113, targeting basal cell carcinomas in Gorlin syndrome, shows promising lesion shrinkage and a favorable safety profile.

The stock of Krystal Biotech (NASDAQ: KRYS), a company that develops treatments for rare diseases, is gaining attention. Its approved product, Vyjuvek, treats dystrophic epidermolysis bullosa, a condition that makes skin fragile. Citigroup (NYSE: C) maintains its Buy rating and raises its price target to $416.00 from $386.00. The stock trades at about $333.32 when the update is posted.

The new target is $82.68 above that share price, or about 24.8%. A price target is an analyst’s estimate of where a stock could trade, not a guarantee. Krystal Biotech is up $2.63, or 0.79%, at $333.32. Its shares have traded between $183.03 and $382.54 over the past year.

Krystal Biotech is also testing KB113 for basal cell carcinomas in people with Gorlin syndrome. As highlighted by GlobeNewswire, more than 80% of assessed lesions shrink across three treated patients, including some that are not directly injected. Tissue analysis confirms that one injected lesion in each patient clears completely.

All reported side effects are mild to moderate and temporary. The results offer early evidence that KB113 may work, but a study of three patients cannot establish how well it works in a larger group. Study investigator Dr. Shireen Guide is scheduled to present the data at the PeDRA Annual Conference on October 15–17, 2026.

As highlighted by Seeking Alpha, an analysis rates Krystal Biotech a Buy and reports $119.2 million in second-quarter Vyjuvek revenue, $1.1 billion in cash and a 40% operating margin. It puts the stock’s valuation at roughly 12 times forward earnings, meaning its share price is about 12 times estimated earnings per share.